Ignorer la navigation

résumé audio créé automatiquement
résumé audio créé automatiquement

Editorial Rating

9

Qualities

  • Overview
  • For Experts

Recommendation

Quantum computing might be the newest buzzword, but it also might represent the chief disruptive technology through 2040. Forward-looking leaders in biopharma R&D will appreciate Boston Consulting Group’s white paper outlining quantum computing’s potential uses and impacts in drug development. Matt Langione, Jean-François Bobier, Chris Meier, Sebastian Hasenfuss and Ulrik Schulze outline the technology’s potential and urge biopharma leaders to begin preparing now.

Take-Aways

  • Quantum computing could revolutionize pharmaceutical R&D in coming decades.
  • Quantum computing promises to enhance quality, speed and cost in the early stages of biopharma R&D.
  • The impact will arrive in phases, beginning with quantum-inspired, computer-aided drug discovery.

About the Authors

Matt Langione is a project leader, Jean-François Bobier is a partner and associate director, Christoph Meier is a principal, and Sebastian Hasenfuss is a consultant at the Boston Consulting Group. Ulrik Schulze, a managing director and senior partner at BCG, leads the firm’s global biopharmaceutical sector.